Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide LAR vs Dulaglutide on BP Variability in T2DM
NCT03444142Phase 4Unknown
- Sponsor
- Universidad de Guadalajara
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide, dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Universidad de Guadalajara. Status: unknown.
02
Drugs
exenatidedulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03444142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444142.